Centre for Probe Development & Commercialization (CPDC) Appoints New CEO and President

October 3, 2018 CPDC

Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will maintain his role as the Principal Investigator on CPDC’s grants and as a member of CPDC’s Board of Directors, providing support to management and to McMaster University as CPDC’s host institution. CPDC has appointed Dr. Joe McCann, CPDC’s current Chief Operating Officer, as its new CEO and President, effective immediately.

“It has been an honour to work with so many great partners over the past 10 years and to watch CPDC continue to grow and deliver value to patients, our stakeholders and employees,” stated Dr. Valliant. “I am fortunate that I will continue to be associated with such an important organization and will continue working with CPDC’s Board of Directors and the talented management team led by new CEO Dr. Joe McCann.”

Dr. Robert Sutherland, Chair of CPDC, said in a statement: “We would like to thank John for his significant contributions to CPDC over the last 10 years, and we look forward to John continuing to shape the vision of CPDC as its Principal Investigator and as a Board Member. John has built a strong management team with the experience, expertise and track record of success that will lead CPDC well into the future as it works to deliver on new initiatives that will position Canada at the forefront of the rapidly growing radiopharmaceutical sector. We are delighted to welcome Joe McCann as CPDC’s new CEO. His expertise, knowhow and knowledge in the radiopharmaceutical space are an excellent fit to deliver on CPDC’s commitments to advancing imaging research and delivering on new initiatives in medical isotopes.”

Dr. McCann joined CPDC in 2010. He has held roles of increasing responsibility over this time and has made significant contributions toward CPDC’s success of the last eight years, including
playing a key role in CPDC receiving a record third round of funding from the Centres of Excellence for Commercialization and Research (CECR), with support from numerous industry and academic partners. The CECR program is part of the Networks of Centres of Excellence of Canada program (NCE).

Dr. McCann commented: “I am honoured to be named CPDC’s CEO and President, and I would like to thank John, Bob and my colleagues for the support and mentorship they provided over the years that prepared me for this role. The radiopharmaceutical space is expanding rapidly and our third round of CECR program funding, and continued support from The Ontario Institute for Cancer Research (OICR) and McMaster University, positions us well to stay at the forefront of the industry and deliver on our commitments to stakeholders and the research community in Ontario and Canada.”

About CPDC
The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.

Contacts
Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212
cpdc@imagingprobes.ca

More news from CPDC

CPDC Announces Appointment of Justyna Kelly as Permanent CEO

Hamilton, Ontario June 23, 2020 The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18, 2020. Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie, outgoing Chair of

ARTMS Closes a US$19 Million Series A Financing with Deerfield and Global Health Sciences (GHS) Fund

VANCOUVER, Canada and NEW YORK, United States, May 20, 2020 – ARTMS Inc. a global leader in developing technology that transforms the production of the world’s most-used diagnostic imaging isotopes, today announced that it has raised US$19 million in a Series A financing. The investment was led by New York based Deerfield Management Company with

CPDC’s Radiopharmaceutical Manufacturing Facility Receives Clearance from FDA

Hamilton, Ontario, Canada – January 9, 2020 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that, following a successful U.S. Food and Drug Administration (FDA) inspection in July, CPDC’s site in Hamilton, Ontario, is cleared to ship products to the U.S.  Justyna Kelly, interim

For more information contact us at: